When a brand asks us for a skin longevity product, the hardest part of the project is usually decided before anyone weighs an ingredient.
Written & researched by Edan Foo, Assistant General Manager & Manufacturing Industry Practitioner · Technical input by ORIZI Group R&D Team · Fact-checked by Creaton Poh · Published by ORIZI Group · Last reviewed August 2026
Disclosure: This article is published by ORIZI Group and may refer to our own manufacturing experience, services and capabilities. External factual claims are supported by cited sources.
Quick answer: what does a skin longevity brief really ask a manufacturer to do?
A skin longevity brief asks a manufacturer to build a product whose main selling point is a biological mechanism that most cosmetic labels are not allowed to describe. In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA) lists references to cell regeneration, DNA repair, skin metabolism and reversing the ageing process as unacceptable cosmetic claims, while “slows down or delays signs of ageing” is acceptable. So the first thing we do with a longevity brief is not formulation — it is working out which sentence the product is eventually allowed to say, and what evidence that sentence will need.
Key takeaways
- Longevity briefs arrive with the marketing story already written. The formulation questions are usually easier to answer than the claims questions.
- Malaysia’s cosmetic claims guideline restricts the exact mechanism vocabulary that skin longevity marketing depends on — and the restriction covers advertising and promotional material, not only the carton.
- The evidence a longevity claim needs is a separate budget line with its own lead time. It is the item most often missing from a first brief.
- An active supplier’s study describes the raw material at a stated concentration in a stated test vehicle. It is not evidence about a finished formula, and we cannot treat it as though it were.
- The version of a longevity product that reaches market successfully is normally the modest, measured one — a defensible number attached to permitted wording.
Scope of this article
This is written from the perspective of a contract manufacturer receiving a brief, not from a laboratory bench. It covers topical cosmetic and personal care products intended for the Malaysian and wider ASEAN market, and it discusses claims, evidence, sequencing and project risk. It does not recommend ingredients, does not report results from any specific ORIZI project, and is not regulatory advice. Where we describe a mechanism or a regulatory position, the source is linked; where we describe how a project tends to behave, that is our own operational observation and is labelled as such.
What does a skin longevity brief usually contain?
Skin longevity is the idea that skincare should support how skin functions over time rather than only improve how it looks today. The scientific framing behind it is genuine. A 2025 review in Frontiers in Aging proposed a working definition built on the established hallmarks of ageing — cellular senescence, mitochondrial dysfunction, epigenetic change, loss of proteostasis and others — and introduced the term skinspan for sustained skin viability, structure and function. The same review is candid that the commercial term itself “remains undefined and unsupported by peer-reviewed scientific literature.”
That gap is exactly what we see arriving in briefs. A longevity brief usually contains three things: a named active or family of actives (peptides, polyphenols, fermentation-derived materials, polydeoxyribonucleotide, exosome-inspired ingredients), a supplier’s technical dossier explaining a mechanism, and a set of draft marketing lines written from that dossier. The formulation request is often the least developed part of the document.
None of that is a criticism of the brand. The supplier material is genuinely interesting, and a founder reading it is right to be excited. The difficulty is structural: the mechanism is the reason the ingredient costs what it costs, and the mechanism is the part the label cannot repeat.
Why we look at the label before we look at the formula
Because the claim decides whether the project is worth building. Annex I Part 8 of the Guidelines for Control of Cosmetic Products in Malaysia sets out a five-step test for whether a proposition is a cosmetic at all, and then lists worked examples of acceptable and unacceptable claims. For skin products, references to the production of collagen and elastin, to DNA repair, to skin metabolism, to cell regeneration and to preventing or reversing the ageing process all sit in the unacceptable column. “Slows down or delays signs of ageing” sits in the acceptable one.
Two details in that guideline change how we sequence a project. The first is the fifth question in the decision process: a product that permanently restores, corrects or modifies physiological function through pharmacological, immunological or metabolic action is not a cosmetic. Longevity language moves towards that description by design, which is why wording is a scoping question and not a finishing touch. The second is that the assessment considers promotional literature, testimonials, advertisements and the audience being targeted — so a compliant carton can still be undermined by a founder interview or an affiliate video.
Here is roughly how a first-pass review looks on our side.
| What the brief says | What we check first | Usual outcome |
|---|---|---|
| “Boosts collagen synthesis” | Whether the phrase can appear on a notified Malaysian product | Reworded to firmness and wrinkle-appearance language |
| “Repairs cellular damage” | Whether it crosses the physiological-function test | Removed from consumer-facing copy; kept in trade material only |
| “Clinically proven” | Whose study, on which formula, at what concentration | Study is on the active, not the finished product — new testing scoped |
| “Visible results in 14 days” | Whether a substantiating study exists or is budgeted | Retained if a study is commissioned; a quantitative claim is permitted when substantiated |
| Growth-factor or cell-diagram artwork | Guideline restrictions on imagery referring to substances of human origin | Artwork direction changed early, before design costs are incurred |
ORIZI Group operational review pattern, August 2026. Claim status readings follow NPRA Annex I Part 8; the guideline states its examples are not exhaustive, and a notification outcome depends on the whole product proposition.
Where longevity projects actually stall
In our experience the delay is rarely chemistry. Three patterns account for most of it.
The evidence was never budgeted. A brand that wants a measured claim needs a study, and a study has a cost, a laboratory and a calendar. When substantiation is discovered late, the choice becomes an unplanned expense or a weaker claim after the artwork has been signed off — and artwork changes late in a project are expensive in their own right.
The supplier study was mistaken for product evidence. This is the most common single issue we raise. An ingredient dossier describes what a raw material did at a specific percentage in a specific test system. A finished formula uses the concentration the brand can afford, in the base the brand chose, alongside a preservative system, a fragrance and a pack. The number does not transfer across that gap, and a brand that prints it anyway cannot defend it.
The claim and the formula were developed by different people. When marketing copy is finalised before the claim review, the formulation team is asked to justify a sentence rather than build a product. Reversing that order — agree the permitted sentence, then build to it — costs nothing at the start of a project and a great deal in the middle of one.
The ORIZI perspective: what we ask in the first meeting
Based on ORIZI Group’s manufacturing experience, we have found it more useful to open a longevity discussion with three questions than with a formulation proposal. This is our own working practice rather than an industry standard, and it is deliberately simple.
- Which markets is this product being notified in? Malaysia publishes an explicit list of unacceptable phrases; the European Union instead requires that whatever you claim is supported under the common criteria for cosmetic claims. A product sold into both is designed to satisfy the stricter reading of each.
- What is the one sentence this product must be able to say? If that sentence is not permissible, the concept needs to change before development starts. If it is permissible but unsupported, it needs a study.
- Who is paying for the substantiation, and when is it booked? Naming the laboratory and the month at the briefing stage removes the most common source of late-stage disruption.
What we notice from working through those questions is that the products that reach market cleanly are usually the modest ones. A brand that states precisely what was measured, over what period, in how many subjects, ends up with copy that survives a notification review and reads as more credible than a mechanism claim that cannot be checked. That has been consistent enough that we now treat it as the default recommendation rather than a compromise.
We have written before about the same tension in other categories — what changes in the lab when a brief says “make it for sensitive skin”, and how a clean and natural brief becomes a preservation problem first. Longevity follows the same shape: a marketing word arrives, and the real work is translating it into something buildable and defensible. On the ingredient side, our R&D team has looked at structural skin actives in this space with the same caution about what the resulting label may say.
Risks and limitations
Everything above is a general description of how briefs of this type behave, not a guarantee about any specific project. Claim acceptability depends on the complete product proposition, including artwork, advertising and target audience, and NPRA reserves the right to disallow wording it considers misleading even where that wording is not on a published list. The Malaysian guideline cited here was issued in August 2022 and states that it is not exhaustive and is subject to review. Costs and timelines for substantiation vary widely by claim tier, laboratory and market, and we do not quote a single figure because an honest one does not exist. This article is not regulatory or legal advice; confirm wording with your notification holder and the relevant authority for each market. Any product touching medical claims falls outside cosmetic scope entirely and requires separate technical and regulatory review.
Frequently asked questions
Can ORIZI Group manufacture an anti-ageing skincare product for my brand?
ORIZI Group manufactures selected cosmetic and personal care formats through its relevant companies, including skincare in the anti-ageing category. What a specific project requires depends on the format, the actives, the packaging and the claim you intend to make. The most useful first step is to share the intended claim alongside the product concept, because the two are assessed together. Our OEM anti-ageing skincare page outlines the formats we work with.
If the label cannot mention the mechanism, is the expensive active still worth using?
It can be, but the justification changes. The active has to earn its cost through a measurable outcome you are permitted to claim — a texture, firmness or wrinkle-appearance result that a study can support — rather than through the mechanism story alone. If the same measurable outcome is achievable at a lower cost with a different system, that is worth knowing before the formula is locked. Decide what you need to measure first, then choose the actives that deliver it.
How long does substantiation testing add to a development timeline?
It depends on the claim tier and the laboratory’s queue rather than on the formula. A consumer-perception panel is the shortest option; instrumental testing with a control arm takes longer and requires a stable, final formula before it can start; biomarker or biopsy-supported work is longer again and is uncommon at typical launch scale. The practical point is that testing cannot begin until the formula is final, so it sits after development rather than alongside it. Book the slot when the formula is approved, not when the artwork is.
Is “anti-ageing” itself a restricted claim in Malaysia?
No. NPRA’s guideline treats claims about the ageing process differently from claims about its visible signs: preventing, reducing, reversing or delaying the ageing process is listed as unacceptable, while “slows down or delays signs of ageing” is listed as acceptable. Most workable anti-ageing copy in this market lives in the appearance register. Check each proposed phrase against the worked examples in Annex I Part 8 before design work begins.
Does this apply to beauty supplements as well as topical skincare?
No. Products intended to be ingested fall outside the cosmetic definition entirely, because a cosmetic must be applied to defined external parts of the body. Beauty-from-within formats sit under a different regulatory framework with its own claim rules. A brand running a topical product and an ingestible under one longevity story is managing two separate claim frameworks and should brief them separately from the start.
Sources and references
- NPRA, Guidelines for Control of Cosmetic Products in Malaysia, Annex I Part 8 — Guideline for Cosmetic Claims (August 2022).
- Klinngam W. et al., “Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims”, Frontiers in Aging 6:1586999 (2025).
- Commission Regulation (EU) No 655/2013 laying down common criteria for the justification of claims used in relation to cosmetic products.
- Source / inspired by: the theme of this article — anti-ageing shifting from surface correction towards biological longevity — is drawn from Azelis Personal Care’s inspiration material, Skin longevity and wellness focus in Personal Care. The operational commentary here is our own.
- Further reading: a market-side analysis of the same subject, written independently of ORIZI Group, is available at OEM Hallmark: Skin Longevity Claims — What a Cosmetic Label May Say.
Update history
27 August 2026 — first published.
If you are working on a longevity concept
If your team is weighing a skin longevity product, the conversation we find most useful is the early one — before the actives are chosen and long before the artwork is drafted. We are happy to talk through what the claim would need, how the evidence would be sequenced and where the concept might need to change, whether or not it becomes a project with us. You can start with our OEM anti-ageing skincare overview, read how we approach innovation and product R&D, or get in touch with a short outline of what you have in mind.
